ストックスクリーナーアプリを入手
36.70
0.38%
-0.14
前日終値:
$36.84
開ける：
$36.78
24時間の取引高:
1.26M
Relative Volume:
0.50
時価総額：
$10.31B
収益：
$2.08B
当期純損益:
$466.92M
株価収益率:
23.53
EPS:
1.56
ネットキャッシュフロー:
$404.94M
1週間 パフォーマンス:
-0.70%
1か月 パフォーマンス:
-2.52%
6か月 パフォーマンス:
+41.37%
1年 パフォーマンス:
+54.66%
1日の値動き範囲:
$36.25
$36.94
1週間の範囲:
$36.25
$38.41
52週間の値動き範囲:
$20.14
$40.02
Exelixis Inc Stock (EXEL) Company Profile
EXEL を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
EXEL
Exelixis Inc
|
36.70 | 10.31B | 2.08B | 466.92M | 404.94M | 1.56 |
|
VRTX
Vertex Pharmaceuticals Inc
|
492.69 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
637.36 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
589.15 | 35.93B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
268.46 | 34.75B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
267.39 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
Exelixis Inc Stock (EXEL) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-02-24 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2025-01-27 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2025-01-24 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2024-12-20 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
| 2024-12-17 | ダウングレード | BofA Securities | Buy → Neutral |
| 2024-10-16 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2024-09-19 | 開始されました | UBS | Neutral |
| 2024-04-11 | ダウングレード | Barclays | Overweight → Equal Weight |
| 2023-12-19 | 開始されました | BTIG Research | Buy |
| 2023-12-15 | 開始されました | Citigroup | Buy |
| 2023-09-26 | 開始されました | H.C. Wainwright | Buy |
| 2023-08-22 | 繰り返されました | Oppenheimer | Outperform |
| 2023-08-08 | 開始されました | SVB Securities | Market Perform |
| 2023-07-11 | 再開されました | Morgan Stanley | Equal-Weight |
| 2023-05-10 | 再開されました | Piper Sandler | Overweight |
| 2023-03-09 | 開始されました | Wells Fargo | Overweight |
| 2023-01-26 | 開始されました | Credit Suisse | Outperform |
| 2022-10-18 | 開始されました | JMP Securities | Mkt Outperform |
| 2022-06-24 | 開始されました | BMO Capital Markets | Outperform |
| 2021-11-19 | 開始されました | Piper Sandler | Overweight |
| 2021-11-03 | 再開されました | Jefferies | Buy |
| 2021-10-07 | 開始されました | Jefferies | Buy |
| 2021-08-06 | 繰り返されました | H.C. Wainwright | Buy |
| 2021-06-15 | 開始されました | H.C. Wainwright | Buy |
| 2021-05-18 | 再開されました | Goldman | Sell |
| 2021-03-31 | 開始されました | Credit Suisse | Outperform |
| 2021-03-12 | 開始されました | Wolfe Research | Outperform |
| 2020-03-04 | 開始されました | Barclays | Overweight |
| 2020-01-13 | 開始されました | SunTrust | Buy |
| 2019-11-13 | 開始されました | BofA/Merrill | Buy |
| 2019-03-18 | アップグレード | Morgan Stanley | Underweight → Equal-Weight |
| 2018-09-17 | 開始されました | Goldman | Neutral |
| 2018-09-10 | 開始されました | Morgan Stanley | Underweight |
| 2018-05-11 | 繰り返されました | Needham | Buy |
| 2017-10-17 | 繰り返されました | Needham | Buy |
| 2017-10-17 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2017-10-16 | 繰り返されました | SunTrust | Buy |
| 2017-09-22 | ダウングレード | Leerink Partners | Outperform → Mkt Perform |
| 2017-09-15 | 開始されました | RBC Capital Mkts | Outperform |
| 2017-09-12 | 繰り返されました | Needham | Buy |
| 2017-07-14 | 開始されました | SunTrust | Buy |
| 2017-03-31 | 開始されました | Needham | Buy |
| 2017-03-16 | 開始されました | Oppenheimer | Perform |
| 2017-02-28 | ダウングレード | Stifel | Buy → Hold |
| 2016-11-03 | 開始されました | Deutsche Bank | Buy |
| 2016-10-10 | アップグレード | Piper Jaffray | Neutral → Overweight |
| 2016-09-15 | 繰り返されました | Stifel | Buy |
すべてを表示
Exelixis Inc (EXEL) 最新ニュース
Exelixis gets FDA nod for its advanced neuroendocrine tumor treatment - MSN
Exelixis stock holds $40 target post FDA nod By Investing.com - Investing.com South Africa
FDA Expands Exelixis Cabometyx Label For Neuroendocrine Tumors - Barchart
FDA Expands Exelixis Cabometyx Label for Neuroendocrine Tumors - Yahoo Canada Finance
Exelixis’ cabozantinib approval ‘certainly positive,’ says Citi - Yahoo Finance
Truist Financial Reaffirms Their Buy Rating on Exelixis (EXEL) - The Globe and Mail
Exelixis stock holds $40 target post FDA nod - Investing.com India
Stifel maintains Exelixis stock hold, $36 target post FDA nod By Investing.com - Investing.com South Africa
FDA approves new treatment for advanced neuroendocrine tumors By Investing.com - Investing.com South Africa
Exelixis to present positive preclinical data across pipeline portfolio at AACR - Yahoo Finance
Leerink lifts Exelixis stock target to $33 post FDA approval By Investing.com - Investing.com Australia
Exelixis Stock Rises 13.3% Year to Date: Buy, Sell or Hold? - TradingView
Leerink lifts Exelixis stock target to $33 post FDA approval - Investing.com India
Stifel maintains Exelixis stock hold, $36 target post FDA nod - Investing.com India
Exelixis’ primary cancer drug wins FDA approval for neuroendocrine tumors - Endpoints News
FDA Approves Exelixis' Lead Cancer Drug Cabometyx For Expanded Use In Neuroendocrine Tumors - Benzinga
Exelixis (NasdaqGS:EXEL) Celebrates FDA Approval For Expanded CABOMETYX® Use In Treating NET - Yahoo Finance
Citi maintains Buy on Exelixis stock with $45 target By Investing.com - Investing.com Canada
Citi maintains Buy on Exelixis stock with $45 target - Investing.com India
Exelixis' cancer drug gets FDA approval but analysts say its priced in; shares down - TradingView
Exelixis wins FDA label expansion for Cabometyx (EXEL:NASDAQ) - Seeking Alpha
Exelixis Gets Expanded FDA Approval of Cabometyx in Advanced Neuroendocrine Tumors - MarketWatch
Here's Why Exelixis (EXEL) is a Strong Growth Stock - Yahoo Finance
Exelixis Announces U.S. FDA Approval Of CABOMETYX® (cabozantinib) For Patients With Previously Treated Advanced Neuroendocrine Tumors - Marketscreener.com
FDA approves new treatment for advanced neuroendocrine tumors - Investing.com
Exelixis Announces U.S. FDA Approval of CABOMETYX® (cabozantinib) for Patients with Previously Treated Advanced Neuroendocrine Tumors - Joplin Globe
(cabozantinib) for Patients with Previously Treated Advanced Neuroendocrine Tumors - Business Wire
Exelixis to Present Positive Preclinical Data Across Its Pipeline Portfolio for Advanced Cancers at AACR 2025 - BioSpace
Looking Into Exelixis's Recent Short Interest - Benzinga
Exelixis (NASDAQ:EXEL) shareholders have earned a 16% CAGR over the last five years - Simply Wall St
Biotech Leader Exelixis Eyes Buy Point In Today's Stock Market Rally - MSN
Learn to Evaluate (EXEL) using the Charts - Stock Traders Daily
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick - Yahoo Finance
Exelixis Growth Continues with Big Money Boosts - Yahoo Finance
Exelixis, Inc. (EXEL): Among the Best Biotech Stocks to Buy According to Billionaires - Yahoo Finance
15 Best Biotech Stocks to Buy According to Billionaires - Insider Monkey
What 25 Analyst Ratings Have To Say About Exelixis - Benzinga
Exelixis: Pinning Hopes On Cracking One Of The Toughest Nuts (NASDAQ:EXEL) - Seeking Alpha
Exelixis (EXEL) Up 13.4% Since Last Earnings Report: Can It Continue? - Yahoo Finance
Exelixis at Leerink Global Healthcare Conference: Strategic Growth and Innovation - Investing.com UK
Exelixis at Barclays Healthcare Conference: Strategic Pipeline Progress By Investing.com - Investing.com UK
Exelixis stock hits 52-week high at $39.3 amid robust growth - Investing.com Australia
Exelixis stock hits 52-week high at $39.3 amid robust growth By Investing.com - Investing.com South Africa
(EXEL) Trading Report - Stock Traders Daily
Global Prostate Cancer Market to Reach USD 29.2 Billion by 2035, Driven by Aging Population and Awareness | Future Market Insights, Inc. - GlobeNewswire Inc.
Proficio Capital Partners LLC Makes New Investment in Exelixis, Inc. (NASDAQ:EXEL) - Defense World
Exelixis, Inc. (NASDAQ:EXEL) Shares Sold by US Bancorp DE - Defense World
Smartleaf Asset Management LLC Increases Holdings in Exelixis, Inc. (NASDAQ:EXEL) - Defense World
Why the Global Cancer Market Could Surpass $900 Billion—And the Stocks Leading the Charge - Morningstar
Exelixis, Inc. to Host Earnings Call - ACCESS Newswire
Equities Analysts Issue Forecasts for Exelixis Q1 Earnings - Defense World
Exelixis Inc (EXEL) 財務データ
収益
当期純利益
現金流量
EPS
0.39%
0.34%
大文字化:
|
ボリューム (24 時間):